IR
MRNA icon

Invictus RG’s Moderna MRNA Stock Holding History

Invictus RG’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-222
Closed -$23K – 23
2020
Q4 		$23K Buy
+222
New +$22.5K 0.23% 49

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Invictus RG's MRNA Position: Q1 2021 in Review

Invictus RG sold out of Moderna (MRNA) in Q1 2021, closing a stake of 222 shares — an estimated $23K sold.

Invictus RG first reported a position in MRNA in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • Invictus RG reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
  • Invictus RG sold 222 Moderna shares in Q1 2021, an estimated $23K.
  • Invictus RG first reported a position in Moderna in Q4 2020 and held it in 1 quarter.
  • Invictus RG's Moderna position peaked at $23K in Q4 2020.
  • 776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Invictus RG's 13F filing for Q1 2021, filed 14 May 2021.